Synergistic Effects of the RAR<i>alpha</i> Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation

Synergistic Effects of the RAR<i>alpha</i> Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation

Inhibition of menin in acute myeloid leukemia (AML) harboring histone-lysine-<i>N</i>-methyltransferase 2A rearrangement (KMT2Ar) or the mutated Nucleophosmin gene (NPM1c) is considered a novel and effective treatment approach in these patients. However, rapid acquisition of resistance m...

Full description

Bibliographic Details
Main Authors: Maximilian Fleischmann, Julia Bechwar, Diana Voigtländer, Mike Fischer, Ulf Schnetzke, Andreas Hochhaus, Sebastian Scholl
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Cancers
Subjects:
menin
RARA
synergy
NPM1
revumenib
tamibarotene
Online Access:https://www.mdpi.com/2072-6694/16/7/1311

Similar Items

Similar Items